Q2 FY2026 EarningsQ2 FY26 results exceeded expectations across major financial metrics, with revenue of $2.8M significantly beating the $0.6M consensus ($4.4M in CNY) due to regulatory milestones from Simcere. GAAP EPS of -$0.27 outperformed the -$0.32 consensus, despite an 85% YoY surge in R&D spending to $16.3M to support Phase 2 Seabreeze STAT trials. Management confirmed a cash runway extending at least one year and expects pivotal topline data for asthma and COPD treatments in September 2026.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Connect Biopharma(CNTB) the Revenue is 2.748 M (+5621%), Beat estimate;the EBIT is -17.47 M (-30.09%), Beat estimate;the EPS is -0.27 (-17.39%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.00B5620.59%
0.00B1253.53%
+0.00B4,367.06%
EBITExceed expectations
-0.02B30.09%
-0.02B46.72%
+0.00B16.63%
EPSExceed expectations
-0.2717.39%
-0.315737.27%
+0.045719.88%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf